Experience of the Lutein drugs use for the treatment of dysmenorrhea
Keywords:progesterone, dysmenorrhea, Lyuteina
Treatment of dysmenorrhea is a very important question. Dysmenorrhea is a cyclic pathological process, manifested by pain in the lower abdomen in the days of menstruation and is accompanied by emotional-mental, vegetative, vegetative-vascular and metabolic endocrine symptoms. Dysmenorrhea is divided into primary, in which you cannot identify pathological changes in the genital organs, and secondary, associated with gynecological diseases (most often inflammatory diseases of the genital organs and endometriosis).
Drugs that are used for dysmenorrhea treatment are often characterized by the presence of side effects, inconvenience for the patient or the high cost.
Aim. To analyze drugs use for the treatment of dysmenorrhea.
Metods and results. There were 66 patients with dysmenorrhea under our supervision. Patients were divided into two groups of 33 women. Patients with dysmenorrhea of the first group have been treated within 6 months receiving the drug Lutein. The second group of women got synthetic progestins.
Conclusion. There is evidence that Lutein is an optimal choice because of its efficiency, an affordable price, a comfortable mode of use and rare side effects.
Vikhlyaeva, E. M. (2000) Rukovodstvo po e′ndokrinnoj ginekologii [Guide endocrine gynecology]. Moscow: MIA [in Russian].
Solov′eva, G. M. (Ed) (2007) Akusherstvo i ginekologiya [Obstetrics and Gynecology]. Moscow: GEOTAR MEDICINA [in Russian].
Pshenichnikova, T. Ya. (2001) Besplodie v brake [Infertility in marriage]. Moscow: Medicine [in Russian].
Starkova, N. T. (Ed.) (2006) Rukovodstvo po klinicheskoj e′ndokrinologii [Manual of Clinical Endocrinology]. Saint Petersburg: Peter [in Russian].
Kulakov, V. I. (2000) E′ndokrinnoe besplodie u zhenshchin. Diagnostika i lechenie: prakticheskoe rukovodstvo [Endocrine infertility in women. Diagnosis and treatment. A practical guide]. Moscow [in Russian].
Cicinelli, E., de Ziegler, D., Bulletti, C., Matteo, M. G., Schonauer, L. M., & Galantino, P. (2000) Direct transport of progesterone from vagina to uterus. Obstet Gynecol, 95, 403–6
Condous, G. (2004) The management of early pregnancy complications. Best PraResearch Clinical Obstetrics and Gynecology, 18, 37–57. doi:10.1016/j.bpobgyn.2003.09.011.
DeCherney, A. N., & Nathan, L. (2003) Current obstetric & gynecologic diagnosis & treatment. Los Angeles: McGraw – Hill.
Levy, T., Gurevitch, S., Bar-Hava, I., Ashkenazi, J., Magazanik, A., Homburg, R., et al. (1999) Pharmacokinetics of natural progesterone administered in the form of vaginal tablet. Hum Reprod, 14, 606–10.
Shantha, S., Brooks-Gunn, J., Locke, R. J., & Warren, M. P. (2001) Natural vaginal progesterone is associated with minimal psychological side effects: a preliminary study. J Women's Health Gender - based Med, 10, 991–7.
Spitz, I. M. (2003) Progesterone antagonists and progesterone receptor modulator, an overview. Steroids, 68, 981–3. doi: 10.1016/j.steroids.2003.08.007.
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)